display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
breast cancer - triple negativees-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
camrelizumab plus SOC SHR1210-III-322 SHR1210-III-322

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons